Stock Scorer

Picard Medical, Inc. (PMI)

Picard Medical, Inc. reported revenue of 3M USD for the quarter ending 30 June 2026, up 38.6% from 2.1M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 3M +38.6%
Gross Profit Q2 '26 · ending 30 June 2026 616K —
Operating Income Q2 '26 · ending 30 June 2026 -4.6M —
Net Income Q2 '26 · ending 30 June 2026 -5.7M —
Cost of Revenue Q2 '26 · ending 30 June 2026 2.3M +3.5%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -1.4M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -1.4M —
Shares Outstanding Q2 '26 · ending 30 June 2026 1.9M -76.7%
EPS Q3 '25 · ending 30 September 2025 -44.58 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 4.9M-13.3M-27M—
20242024-12-31 4.4M-13.7M-21.1M—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-303M
Q1 '262026-03-311.1M
Q4 '252025-12-311M
Q3 '252025-09-301.2M
Q2 '252025-06-302.1M
Q1 '252025-03-31620K
Q4 '242024-12-31836K
Q3 '242024-09-30881K
Q2 '242024-06-30694K
Q1 '242024-03-312M

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-30616K
Q1 '262026-03-31275K
Q4 '252025-12-31411K
Q3 '252025-09-30-130K
Q2 '252025-06-30-127K
Q1 '252025-03-31-358K
Q3 '242024-09-30-673K
Q2 '242024-06-30-382K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-4.6M
Q1 '262026-03-31-4.5M
Q4 '252025-12-31-3M
Q3 '252025-09-30-3.5M
Q2 '252025-06-30-3.5M
Q1 '252025-03-31-3.2M
Q4 '242024-12-31-3.6M
Q3 '242024-09-30-4.4M
Q2 '242024-06-30-3.8M
Q1 '242024-03-31-1.9M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-5.7M
Q1 '262026-03-31-7.6M
Q4 '252025-12-31-4.3M
Q3 '252025-09-30-10.4M
Q2 '252025-06-30-6.7M
Q1 '252025-03-31-5.6M
Q4 '242024-12-31-8.8M
Q3 '242024-09-30-6.2M
Q2 '242024-06-30-4.1M
Q1 '242024-03-31-2M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-302.3M
Q1 '262026-03-31875K
Q4 '252025-12-31598K
Q3 '252025-09-301.3M
Q2 '252025-06-302.3M
Q1 '252025-03-31978K
Q4 '242024-12-31700K
Q3 '242024-09-301.6M
Q2 '242024-06-301.1M
Q1 '242024-03-311.2M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-1.4M
Q1 '262026-03-31-3.8M
Q4 '252025-12-31-4.4M
Q3 '252025-09-30-6.5M
Q2 '252025-06-30-2.5M
Q1 '252025-03-31-2.2M
Q4 '242024-12-31-3.2M
Q3 '242024-09-30-2.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-1.4M
Q1 '262026-03-31-3.8M
Q2 '252025-06-30-2.5M
Q1 '252025-03-31-2.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-301.9M
Q1 '262026-03-3174.4M
Q3 '252025-09-3054.5M
Q2 '252025-06-30177.4K
Q1 '252025-03-318M
Q3 '242024-09-307.9M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '252025-09-30-44.58
Q2 '252025-06-30-45.26